

Patients may or may not meet eligibility requirements as established
by Alberta Government sponsored drug programs.

Please complete all required sections to allow your request to be processed.

| PATIENT INFORMATION | | | | COVERAGE TYPE | |
|-------------------------|--------------------------------|---------|--|---------------------------|--|
| PATIENT LAST NAME | FIRST NAME | INITIAL | <input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other _____ | | |
| BIRTH DATE (YYYY-MM-DD) | ALBERTA PERSONAL HEALTH NUMBER | | | | |
| STREET ADDRESS | CITY | PROV. | POSTAL CODE | ID/CLIENT/COVERAGE NUMBER | |

| PRESCRIBER INFORMATION | | | | | |
|------------------------|------------|---------|---|--------------------------------|---------------------|
| PRESCRIBER LAST NAME | FIRST NAME | INITIAL | PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION | | |
| STREET ADDRESS | | | <input type="checkbox"/> CPSA | <input type="checkbox"/> ACO | REGISTRATION NUMBER |
| | | | <input type="checkbox"/> CARNA | <input type="checkbox"/> ADA+C | |
| CITY, PROVINCE | | | PHONE | FAX | |
| POSTAL CODE | | | FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED | | |

Please provide the following information for ALL requests

| | | | |
|---|---|---------------------------------|----------------------|
| Requested drug | <input type="checkbox"/> Fasenna | <input type="checkbox"/> Nucala | Dosage and frequency |
| Diagnosis | Please indicate if this patient is | | |
| <input type="checkbox"/> Severe Eosinophilic Asthma | <input type="checkbox"/> Starting drug upon approval complete section I | | |
| <input type="checkbox"/> Other (please specify) _____ | <input type="checkbox"/> New to coverage but currently maintained on drug complete section I and II | | |
| | <input type="checkbox"/> Renewing coverage complete section II | | |

Section I: Please provide pre-treatment information for NEW requests for treatment-naive and treatment-experienced patients

| |
|--|
| 1) Blood eosinophil count _____ (cells/mcL) Date _____ |
| 2) Number* of clinically significant exacerbations of asthma within the 12-month period prior to starting the requested drug (defined as worsening of asthma such that the treating physician elected to administer systemic glucocorticoids for at least three days or the patient visited an emergency department or was hospitalized) _____ *Please provide an exact number. If the patient has had no exacerbations it should be reported as 'zero (0)'. |
| 3) Asthma Control Questionnaire (ACQ-5) score _____ Date _____ |
| 4) Current medications: Check all that apply and include name of medication, dose, duration and response |
| <input type="checkbox"/> High-dose inhaled corticosteroids _____ |
| <input type="checkbox"/> Oral corticosteroids (OCS) _____ → Patient requires daily maintenance OCS prior to initiation of requested drug? <input type="checkbox"/> Yes <input type="checkbox"/> No |
| <input type="checkbox"/> Other asthma controllers (e.g. long-acting beta-2 agonist, please specify) _____ |

Section II: Complete the following for all RENEWAL requests and for INITIAL requests for treatment-experienced patients

| |
|---|
| 1) Number* of clinically significant asthma exacerbations within the previous 12-month period while on the requested drug (defined as worsening of asthma such that the treating physician elected to administer systemic glucocorticoids for at least 3 days or the patient visited an emergency department visit or was hospitalized) _____ *Please provide an exact number. If the patient has had no exacerbations it should be reported as 'zero (0)'. |
| 2) Current Asthma Control Questionnaire (ACQ-5) score _____ Date _____ |
| 3) Check if the following applies to the patient in the previous 12-month period while on the requested drug |
| <input type="checkbox"/> A decrease in the daily maintenance OCS dose from pre-treatment baseline |
| <input type="checkbox"/> The reduction in the daily maintenance OCS dose achieved after the first 12 months of therapy has at least been maintained |

Additional information relating to request

| | | |
|--|------|--|
| PRESCRIBER'S SIGNATURE | DATE | Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009 108 Street NW, Edmonton, Alberta T5J 3C5 FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas |
| ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST | | |

